Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07QHF
|
|||
| Former ID |
DIB001332
|
|||
| Drug Name |
SAR-260093
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24N8OS
|
|||
| Canonical SMILES |
CCC1=CN=C(N=C1)N2CCC(CC2)C3=NC(=CS3)COC4=CC=C(C=C4)N5C=NN=N5
|
|||
| InChI |
1S/C22H24N8OS/c1-2-16-11-23-22(24-12-16)29-9-7-17(8-10-29)21-26-18(14-32-21)13-31-20-5-3-19(4-6-20)30-15-25-27-28-30/h3-6,11-12,14-15,17H,2,7-10,13H2,1H3
|
|||
| InChIKey |
NFTMKHWBOINJGM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1037792-44-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose-dependent insulinotropic receptor (GPR119) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Insulin secretion | ||||
| WikiPathways | Incretin Synthesis, Secretion, and Inactivation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01035879) Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes.U.S. National Institutes of Health. | |||
| REF 2 | GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.